First Gene Therapy for Rare Skin Disorder, Offering New Hope for Wound Healing in Dystrophic Epidermolysis Bullosa (DEB)

Vyjuvek™ (beremagene geperpavec), a topical gene therapy for the relief of a rare genetic skin disorder.

Complete End-to-End Solutions Optimise Rare Disease Clinical Trials and Product Commercialisation

Pharmaceutical manufacturers rely upon AscellaHealth as a single resource for managing all phases of rare disease clinical trials.

The Changing Biosimilar Landscape

Biologic medications bring hope to patients suffering from a variety of specialty conditions.

A Look at von Willebrand Disease

An inherited blood clotting disorder caused by either a deficiency or a dysfunction of the von Willebrand factor (vWf) protein.

Pharmaceutical Companies Turn to AscellaHealth for Consultative Business Model, Including Robust Pre-Commercialisation and Market Access Services

Specialty drug manufacturers are seeking innovative approaches to effectively launch new products.

First Gene Therapy for Haemophilia B, HEMGENIX® Approved by the European Commission

Exciting news about conditional marketing authorisation for gene therapy for the treatment of Haemophilia B.

Optimising Market Access for Rare Disease Products – NEW Market Access Guide now available

A step-by-step guide for EU/UK stakeholders to bring products to market.

Potential New Therapies on the Horizon for Duchenne Muscular Dystrophy

New hope for people living with the rare genetic disorder DMD in the UK.

End-to-End Solutions Optimise Rare Disease Clinical Trials and Product Commercialisation

AscellaHealth a trusted Specialty Pharmacy solutions partner for rare disease clinical trials and implementing go-to-market strategies.

Specialty pharmaceutical and rare disease expert adopts name of global parent to reflect breadth of offer that brings a rare and special perspective to the market

Terebellum adopts the name of its global parent, AscellaHealth.

End-to-End Solutions Optimise Specialty Product Access and Market Entry, Enhance Outcomes for Rare Disease Patients

Terebellum and its parent company, AscellaHealth Reflect on Rare Disease Day.

A Look at von Willebrand Disease

An inherited blood clotting disorder caused by either a deficiency or a dysfunction of the von Willebrand factor (vWf) protein.

HUB & Patient Support Solutions Complement Pre-Commercialisation Services

Terebellum’s expanded HUB/ Patient Support Services for Life Sciences manufacturers are recognised as the best-in-class outsourced solutions for successful medication access, compliance and enhanced outcomes.

Re-Think. Re-Consider. Re-Calibrate.

2023 Go-to-Market Strategies for Launching Specialty Drugs, Cell & Gene Therapies

Market Access Guide Launches to Mark Rare Disease Day

Optimising Market Access for Rare Disease Products

Honor Friends, Family and All People with Rare Diseases

February 28, 2023, is Rare Disease Day

Terebellum Provides Insights on Market Access Strategies

The importance of market access and commercialisation strategies to assist patients suffering with rare or orphan diseases.

Pursuing A New Paradigm in Inclusive Research

The significance of clinical trials to provide more robust data, ultimately leading to more effective medicines for patients who need them.